I have always been interested in chemistry and biology. My undergraduate, graduate, and postdoctoral trainings in pharmacy, medicinal chemistry and pharmacology, respectively, have strengthened this interest and led me to realize that significant advances in medicine have frequently been realized because of research at the chem- try–biology interface. I am hoping that this comprehensive volume on recent advances in bioactivation research will stimulate pharmacologists, medicinal chemists, phar- ceutical scientists, and graduate students in these fields and related areas to consider and use bioactivation research when they explore and chart new frontiers in drug design and drug development and when they consider ways to reduce the side effects of existing drugs by making prodrugs. As for the toxicologists and environmental health scientists, I hope this volume will help them generate the knowledge needed to understand better mechanisms of toxicity to improve human risk assessments and intervention methods after occupational or environmental exposure to various hazardous chemicals. Adnan A. Elfarra, Ph. D. vii Part I General Concepts and Basic Mechanisms 1 Metabolic Concerns in Drug Design Jeffrey P. Jones Department of Chemistry, Washington State University, Pullman, WA 99164, USA e-mail: jpj@wsu. edu Keywords: Cytochrome P450 Aldehyde Oxidase Drug–Drug Interactions Mechanism-based Virtual Screening ADMET Regioselectivity 1. 1. Introduction Due to recent technological innovations, such as genomics, combinatorial chemistry, and high-throughput screening, the identification of disease targets and of compounds that are active against these targets (‘‘leads’’) can now be carried out efficiently.
Author(s): Jeffrey P. Jones (auth.), Adnan Elfarra (eds.)
Series: Biotechnology: Pharmaceutical Aspects IX
Edition: 1
Publisher: Springer-Verlag New York
Year: 2008
Language: English
Pages: 440
Tags: Pharmacology/Toxicology; Immunology
Front Matter....Pages 1-7
Front Matter....Pages 1-1
Metabolic Concerns in Drug Design....Pages 1-24
Role of Bioactivation in Idiosyncratic Drug Toxicity: Structure–Toxicity Relationships....Pages 1-29
Michael Addition–Elimination Reactions: Roles in Toxicity and Potential New Therapeutic Applications....Pages 1-12
Induction of Drug-Metabolizing Enzymes: Contrasting Roles in Detoxification and Bioactivation of Drugs and Xenobiotics....Pages 1-34
Mechanism-Based Inactivation of Cytochrome P450 2A and 2B Enzymes....Pages 1-29
CYP2E1 – Biochemical and Toxicological Aspects and Role in Alcohol-Induced Liver Injury....Pages 1-36
One- and Two-Electron-Mediated Reduction of Quinones: Enzymology and Toxicological Implications....Pages 1-29
Lipoxidation-Derived Electrophiles as Biological Reactive Intermediates....Pages 1-34
Bioactivation and Protein Modification Reactions of Unsaturated Aldehydes....Pages 1-21
Front Matter....Pages 1-1
Adaptive Responses and Signal Transduction Pathways in Chemically Induced Mitochondrial Dysfunction and Cell Death....Pages 1-33
Hepatic Bioactivation and Drug-Induced Liver Injury....Pages 1-33
Role of Cysteine S-Conjugate β-Lyases in the Bioactivation of Renal Toxicants....Pages 1-24
Bioactivation of Xenobiotics in Lung: Role of CYPs and FMOs....Pages 1-27
Generation of Reactive Metabolites and Associated DNA Adducts from Benzene, Butadiene, and PAH in Bone Marrow. Their Effects on Hematopoiesis and Impact on Human Health....Pages 1-34
Butadiene-Mediated Mutagenesis and Carcinogenesis....Pages 1-31
Pharmacogenetics of Drug Bioactivation Pathways....Pages 1-20
Human Phenanthrene Metabolites as Probes for the Metabolic Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons....Pages 1-22
Back Matter....Pages 1-19
